Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
Q9H0Z9
UPID:
RBM38_HUMAN
Alternative names:
CLL-associated antigen KW-5; HSRNASEB; RNA-binding motif protein 38; RNA-binding region-containing protein 1; ssDNA-binding protein SEB4
Alternative UPACC:
Q9H0Z9; A6NDK1; A6NMU6; Q15350; Q15351; Q9BYK3; Q9BYK4
Background:
RNA-binding protein 38, known as RNA-binding motif protein 38, plays a crucial role in cellular processes, including mRNA splicing and myogenic differentiation. It specifically binds the 3'-UTR of CDKN1A transcripts, stabilizing them and mediating the p53/TP53 family's regulation of CDKN1A to induce cell cycle arrest. Additionally, it is vital for the splicing of human parvovirus B19 pre-mRNAs, enhancing viral replication.
Therapeutic significance:
Understanding the role of RNA-binding protein 38 could open doors to potential therapeutic strategies.